The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)

類似資料

• Riociguat for pulmonary arterial hypertension associated with congenital heart disease
  著者:: Rosenkranz, Stephan, 等
  出版事項: (2015)
• The clinical development of sGC modulators, riociguat and vericiguat
  著者:: Misselwitz, Frank
  出版事項: (2015)
• Platelet inhibitory effects of the NO independent sGC stimulator riociguat (Bay 63-2561)
  著者:: Reiss, Cora, 等
  出版事項: (2013)
• Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
  著者:: Stephan, Rosenkranz, 等
  出版事項: (2015)
• The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood
  著者:: Reiss, C., 等
  出版事項: (2015)